Swiss Cancer Institute

This study tests whether a reduced dose of chemotherapy combined with the immunotherapy drug cemiplimab works better than cemiplimab alone for people aged 70 and older with advanced non-small cell lung cancer. Participants must be in relatively poor health or frail, and their tum…

This study tests whether terbinafine, a widely used antifungal pill, can slow prostate cancer growth in men whose cancer has returned after initial treatment. It includes 42 participants with rising PSA but no visible tumors on scans. The goal is to delay or avoid standard hormon…

This study tests whether adding doxycycline, a cheap and safe antibiotic, to standard chemotherapy can better target cancer stem cells in early-stage breast cancer. These stem cells are thought to resist treatment and cause cancer to return. About 50 women with ER+/HER2- breast c…

This study is for people with stage IV non-small cell lung cancer whose main tumor and metastases have shrunk after initial chemotherapy, immunotherapy, or targeted therapy. The researchers want to see if also treating the remaining cancer spots with surgery or radiation (called …

This study tests whether adding the drug darolutamide to standard treatments can help men with a hard-to-treat type of advanced prostate cancer (mCRPC). About 162 participants will receive either standard care alone or standard care plus darolutamide, followed by maintenance ther…

This study tests whether adding heat therapy (hyperthermia) to chemotherapy before surgery and radiation is feasible for people with high-risk soft tissue sarcoma in the arms, legs, or trunk. The goal is to see if patients can complete all planned treatments. About 24 adults will…

This phase 2 trial tests whether injecting the drug INT230-6 into the tumor before standard chemotherapy and immunotherapy can increase the chance of eliminating all cancer in the breast and lymph nodes before surgery. About 61 people with early triple-negative breast cancer will…